Explore Your Path Forward With BAXDELA® (delafloxacin)

Broad Coverage: gram-positive pathogens, including MRSA, and gram-negative pathogens, including Pseudomonas aeruginosa


BAXDELA is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following:
Gram-positive organisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis.
Gram-negative organisms: Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Oral Monotherapy Dosing

  • 450-mg tablet q12h
    • No dosing adjustments
    • No food effect

Demonstrated Safety Profile

  • No evidence of QT prolongation was observed in patients taking BAXDELA 300 or 900 mg IV in a definitive QT study vs oral moxifloxacin 400 mg or placebo
  • No clinically significant phototoxic potential was observed in BAXDELA 200 or 400 mg/day oral in a photosafety study vs lomefloxacin as the active comparator
  • Minimal potential for drug interactions demonstrated during development
    • No drug-drug interactions due to CYP450
    • Oral BAXDELA should be taken 2 hours before or 6 hours after antacids or multivitamins containing iron or zinc
    • Do not administer any solution containing multivalent cations (eg, calcium and magnesium) through the same IV line
  • The most common adverse reactions in patients treated with BAXDELA during Phase 3 trials were nausea (8%), diarrhea (8%), headache (3%), transaminase elevations (3%), and vomiting (2%)

Next: Efficacy

BAXDELA® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.